With increasing doses, the elimination half-life also became prolonged. In patients with renal insufficiency, the administration of a single 100 mg dose of moclobemide did not appreciably alter the pharmacokinetics of the drug, except for an increase in absorption time. Indications For the symptomatic relief of depressive illness. Contraindications In patients with a known hypersensitivity to the drug. Moclobemide is also contraindicated in patients in an acute confusional state.
Data involving other tricyclic antidepressants is limited.
Consequently, the concomitant use of moclobemide and tricyclic antidepressants is contraindicated. Clinical data are not available on the concomitant use of moclobemide and selective serotonin reuptake inhibitors or other available MAO inhibitors. Therefore, until such data becomes available, moclobemide should not be administered in combination with these agents. There is no experience with the concomitant use of moclobemide and narcotics. However, death has occurred in patients receiving a nonreversible, nonselective MAO inhibitor and meperidine given concomitantly.